Neurocrine Biosciences: Growth Beyond Just Ingrezza [Seeking Alpha]
Neurocrine Biosciences, Inc. (NBIX)
Last neurocrine biosciences, inc. earnings: 2/4 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
neurocrine.com/about-us/webcasts-presentations
Company Research
Source: Seeking Alpha
NBIX's late-stage neuropsychiatry pipeline, including muscarinic agonist and glutamate modulator programs, appears significantly underappreciated by the market. Ingrezza's revenue growth is slowing due to pricing pressures, but NBIX's robust cash position and pipeline investments support long-term growth into the 2030s. NBIX's balance sheet strength and strategic lifecycle management position it as a growth engine, not a mature biopharma, despite competitive and pricing risks. imaginima/iStock via Getty Images As we move through the first quarter of 2026, I am optimistic about Neurocrine Biosciences ( NBIX ) because they have been able to demonstrate the success of their business development strategy in 2025. They were able This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it exp
Show less
Read more
Impact Snapshot
Event Time:
NBIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NBIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NBIX alerts
High impacting Neurocrine Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
NBIX
News
- Neurocrine Biosciences (NASDAQ:NBIX) had its price target lowered by analysts at Wells Fargo & Company from $180.00 to $175.00. They now have an "overweight" rating on the stock.MarketBeat
- Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at Citigroup Inc. from $203.00 to $204.00. They now have a "buy" rating on the stock.MarketBeat
- Neurocrine Biosciences: Expanding Opportunities, 2026 Will Be Less Exciting [Seeking Alpha]Seeking Alpha
- Neurocrine Biosciences (NASDAQ:NBIX) had its price target lowered by analysts at Royal Bank Of Canada from $180.00 to $177.00. They now have an "outperform" rating on the stock.MarketBeat
- Neurocrine Biosciences (NASDAQ:NBIX) had its price target lowered by analysts at BMO Capital Markets from $147.00 to $140.00. They now have a "market perform" rating on the stock.MarketBeat
NBIX
Earnings
- 2/11/26 - Beat
NBIX
Sec Filings
- 2/11/26 - Form 10-K
- 2/11/26 - Form 8-K
- 2/3/26 - Form 4
- NBIX's page on the SEC website